<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21466683</article-id><article-id pub-id-type="pmc">3226274</article-id><article-id pub-id-type="publisher-id">alzrt71</article-id><article-id pub-id-type="doi">10.1186/alzrt71</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Kok</surname><given-names>Eloise H</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>eloise.kok@uta.fi</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Luoto</surname><given-names>Teemu</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>teemu.luoto@uta.fi</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Haikonen</surname><given-names>Satu</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>satu.haikonen@uta.fi</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Goebeler</surname><given-names>Sirkka</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>sirkka.goebeler@phsp.fi</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Haapasalo</surname><given-names>Hannu</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>hannu.haapasalo@phsp.fi</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Karhunen</surname><given-names>Pekka J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pekka.karhunen@uta.fi</email></contrib></contrib-group><aff id="I1"><label>1</label>School of Medicine, University of Tampere, Medisiinarinkatu 3, 33014 Tampere, Finland</aff><aff id="I2"><label>2</label>National Institute for Health and Welfare, Biokatu 10, 33520 Tampere, Finland</aff><aff id="I3"><label>3</label>Central Laboratory, Tampere University Hospital, Biokatu 4, 33521 Tampere, Finland</aff><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>5</day><month>4</month><year>2011</year></pub-date><volume>3</volume><issue>2</issue><fpage>12</fpage><lpage>12</lpage><history><date date-type="received"><day>1</day><month>3</month><year>2011</year></date><date date-type="rev-recd"><day>22</day><month>3</month><year>2011</year></date><date date-type="accepted"><day>5</day><month>4</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2011 Kok et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Kok et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://alzres.com/content/3/2/12"/><abstract><sec><title>Introduction</title><p><italic>APOE </italic>is the strongest risk gene for sporadic Alzheimer's disease (AD) so far. Recent genome wide association studies found links for sporadic AD with <italic>CLU </italic>and <italic>CR1 </italic>involved in A&#x003b2; clearance, and <italic>PICALM </italic>affecting intracellular trafficking.</p></sec><sec><title>Methods</title><p>We investigated the associations of senile plaques (SP) and neurofibrillary tangles (NFT) with the proposed risk genes and <italic>APOE</italic>, in the Tampere Autopsy Study (TASTY) series (603 cases), a sample of the general population (0 to 97 yrs), who died out-of-hospital.</p></sec><sec><title>Results</title><p>Age and the <italic>APOE</italic>&#x003b5;4 allele associated strongly with all phenotypes of SP, as expected. In age and <italic>APOE</italic>&#x003b5;4 adjusted analyses, compared to the most common homozygous genotype, burnt out SP were more common among carriers of the C-allele of <italic>CLU</italic>, whereas the T-allele of <italic>PICALM </italic>and C-allele of <italic>CR1 </italic>were linked with lower SP coverage. We found no significant associations between any of the genetic variants and NFT.</p></sec><sec><title>Conclusions</title><p>Marginal effects from <italic>CLU</italic>, <italic>CR1 </italic>and <italic>PICALM </italic>suggest that these genes have minimal effects on the development of AD lesions.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Alzheimer's disease (AD) is the most common form of dementia in Western society and is, and will continue to be, a burden on health systems in the future as the population ages. Age is the largest risk factor for the disease, with higher incidences in older populations [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>].</p><p>Identification of genes related to sporadic AD risk has been slow with study groups isolating only one strongly associated gene: <italic>APOE </italic>[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. The epsilon 4 allele of apolipoprotein E (<italic>APOE</italic>&#x003b5;4) provides odds ratios (ORs) of between 3 and 25 [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>] for disease association. APOE&#x003b5;4 is suspected to have a lower effectiveness at transporting cholesterol and is not as efficient at repairing neuronal damage as APOE&#x003b5;3 [<xref ref-type="bibr" rid="B7">7</xref>]. One or even two copies of the allele, however, are not sufficient to cause the disease, as many carriers of two &#x003b5;4 alleles do not develop AD [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Studies aiming to detect genes associated with disease risk have used heterogeneous AD cohorts and ascertained few polymorphisms with only a minor impact on disease incidence. One of the problems is to distinguish between pure AD, vascular dementia and other dementia types in clinical cohorts [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. The only consistent and currently accepted method for confirming AD is with post-mortem assessment of the neuropathological lesions neurofibrillary tangles (NFT) and senile plaques (SP) [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Demented individuals do not always exhibit large enough numbers of SP to warrant an AD diagnosis [<xref ref-type="bibr" rid="B15">15</xref>] and NFT and SP are both relatively common in the general population [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. Furthermore, these lesions do not provide a clear-cut explanation as to the cause of AD, with different theories advocating amyloid beta (A&#x003b2;) accumulation [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B20">20</xref>] or hyperphosphorylated NFT-causing tau protein [<xref ref-type="bibr" rid="B21">21</xref>] as the underlying initiating mechanisms that trigger the disease.</p><p>Two recent extensive genome-wide association studies (GWAS), comprising 12,000 probable AD cases and 18,000 age-matched non-demented controls [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>], revealed three new candidates for genetic risk of developing late onset or sporadic AD: <italic>CLU</italic>, <italic>CR1 </italic>and <italic>PICALM</italic>. Phosphatidylinositol-binding clathrin assembly protein (PICALM) is involved in synaptic neurotransmitter release and intracellular trafficking [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>], whilst complement component (3b/4b) receptor 1 (CR1), the main receptor of complement C3b protein, binds A&#x003b2; and thus may promote clearance [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B30">30</xref>]. Clusterin (CLU, and also known as ApoJ), was replicated independently in the two studies and is thought to bind and remove A&#x003b2; from the brain, as well as assist in re-entry of A&#x003b2; [<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B34">34</xref>].</p><p>We have previously shown that as many as one-third of non-demented individuals in an autopsy series-based sample carry SP and more than 40% NFT, with strong age dependence [<xref ref-type="bibr" rid="B16">16</xref>]. This suggests that in clinical study series, non-demented control patients may not be free of AD-related neuropathological lesions. Utilising this same cohort, we aimed to investigate whether SP and NFT are associated with any of the recently identified GWAS single nucleotide polymorphisms (SNPs); <italic>CLU</italic>, <italic>CR1 </italic>and <italic>PICALM </italic>to examine their involvement in the development of these brain lesions.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Autopsy series</title><p>The Tampere Autopsy Study (TASTY) cohort consisted of 603 autopsy cases, of which the majority died out-of-hospital within Tampere, Finland and surroundings, collected during the years 2002 to 2004 (described in detail elsewhere [<xref ref-type="bibr" rid="B16">16</xref>]). The study was approved by the Board of Medicolegal Affairs of Finland. Females within the cohort accounted for 35.8% and the ages for the entire series ranged from 0 to 97, with an average of 63 years (59 years for males and 68 years for females). Of the cases, 6 (1%) had a clinical AD diagnosis, 16 (2.7%) undefined dementia, 10 (1.7%) had memory disorders and 1 (0.2%) had Parkinson's disease prior to death (according to available hospital records and next of kin reports). In some cases it was impossible to obtain all variables due to technical difficulties and sample damage.</p></sec><sec><title>Alzheimer-related lesion measurements</title><p>SP and NFT staining and measures have be portrayed previously [<xref ref-type="bibr" rid="B16">16</xref>]. Briefly, the Bielschowsky argyrophilic silver impregnation method was performed on samples and measured by two researchers to acquire SP (neocortex) and NFT (hippocampus) counts. Each area was screened to find the highest density of SP (neocortical area at 100 &#x000d7; magnification) and NFT (hippocampus - CA1 area at 200 &#x000d7; magnification) and then scored using a square microscopic grid (SP - 100 intersections covering 1 mm<sup>2</sup>, NFT - four to six random columns), before creating an average percentage of coverage (SP) or average number in 1 mm<sup>2 </sup>(NFT). Bielschowsky staining was highly correlated with Amyloid beta (A&#x003b2;) staining (antibody from Cell Signaling Technology, Danvers, MA, USA; concentration 1:150), which was used to verify our previous results [<xref ref-type="bibr" rid="B16">16</xref>], and used the same cortical coverage of SP method. SP and NFT variables included the following categorisations as measured by a neuropathologist: SP (No, Yes), SP type (No Plaques, Diffuse, Primitive, Classic, Burnt Out), SP type 2 (No Plaques, Non-neuritic SP, Neuritic SP), NFT (No, Yes), where reference groups were those with 'No SP' or 'No NFT' and those with either brain lesion were considered 'affected'. Semi-quantitative data for SP utilised the categories 'no', 'sparse', 'moderate' and 'frequent' SP.</p></sec><sec><title>Genotyping</title><p>The ABI Prism 7900HT Sequence Detection System used 1 &#x003bc;l DNA with PCR primers (Applied Biosystems, Espoo, Finland) for rs11136000 (<italic>CLU</italic>), rs1408077 (<italic>CR1</italic>) and rs3851179 (<italic>PICALM</italic>). All SNPs were in Hardy-Weinberg equilibrium and genotyping confirmed using SDS version 2.2 (Applied Biosystems). Genotyping for <italic>APOE </italic>has been previously described [<xref ref-type="bibr" rid="B16">16</xref>]. Genotyping for the polymorphisms of <italic>CLU</italic>, <italic>CR1 </italic>and <italic>PICALM </italic>were successful for 94%, 97% and 97% of the TASTY cases, respectively.</p></sec><sec><title>Statistics</title><p>Logistic regression analyses, with continuous age and <italic>APOE</italic>&#x003b5;4 carriership as covariates (where possible), were used with SPSS (version 14.0 for Windows; SPSS Finland Oy, Espoo, Finland) to determine associations between the SNPs and AD-related neuropathological lesions. For all SNPs, the most common homozygous genotype was used as the reference group. As previously mentioned, those unaffected by SP or NFT were considered the reference group for the brain lesion categories. When analysing with the cohort split by age groups, the following categories were used: 0 to 49 years, 50 to 59 years, 60 to 69 years, 70 to 79 years, 80+ years, with the youngest group (0 to 49 years) considered the reference group with respect to age, in analyses. The cohort was also split by gender, where mentioned.</p></sec></sec><sec><title>Results</title><sec><title>Autopsy series characteristics</title><p>The Tampere Autopsy Series (TASTY) (<italic>n </italic>= 603) comprises consecutive autopsies on males and females aged 0 to 97 years that lived outside institutions or hospitals (see Table <xref ref-type="table" rid="T1">1</xref>). Females were on average 10 years older than males, but males were more likely to have SP compared to females (odds ratio (OR) 2.15, <italic>P </italic>&#x0003c; 0.0001, 95% confidence intervals (CI) 1.49 to 3.11). When age was divided into five equal-sized groups, each age group was consistently more likely to have SP compared to the youngest group, with each association also highly statistically significant (see Table <xref ref-type="table" rid="T2">2</xref>). This was also true for NFT prevalence (see Table <xref ref-type="table" rid="T2">2</xref>), with females more likely than males to have NFT (OR 2.18, <italic>P </italic>&#x0003c; 0.0001, CI 1.49 to 3.18).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>TASTY cohort characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Age (years)</th><th align="center">0 to 97</th><th align="center">62.67</th></tr></thead><tbody><tr><td align="left">Males</td><td align="center">388</td><td align="center">64.3%</td></tr><tr><td align="left">Cause of Death</td><td/><td/></tr><tr><td align="left">&#x02003;Disease</td><td align="center">59.1%</td><td/></tr><tr><td align="left">&#x02003;Accident</td><td align="center">26.8%</td><td/></tr><tr><td align="left">&#x02003;Suicide</td><td align="center">11.8%</td><td/></tr><tr><td align="left">&#x02003;Homicide</td><td align="center">0.5%</td><td/></tr><tr><td align="left">&#x02003;Unknown</td><td align="center">1.5%</td><td/></tr><tr><td align="left">Dementia Status</td><td/><td/></tr><tr><td align="left">&#x02003;AD</td><td align="center">6</td><td align="center">1%</td></tr><tr><td align="left">&#x02003;Dementia</td><td align="center">16</td><td align="center">2.7%</td></tr><tr><td align="left">&#x02003;Memory Problems</td><td align="center">10</td><td align="center">1.7%</td></tr><tr><td align="left">&#x02003;Parkinson's Disease</td><td align="center">1</td><td align="center">0.2%</td></tr><tr><td align="left">SP</td><td align="center">172</td><td align="center">31.1%</td></tr><tr><td align="left">NFT</td><td align="center">204</td><td align="center">42.1%</td></tr><tr><td align="left">SP type</td><td/><td/></tr><tr><td align="left">&#x02003;Diffuse</td><td align="center">21</td><td align="center">3.7%</td></tr><tr><td align="left">&#x02003;Primitive</td><td align="center">35</td><td align="center">6.2%</td></tr><tr><td align="left">&#x02003;Classic</td><td align="center">83</td><td align="center">14.7%</td></tr><tr><td align="left">&#x02003;Burnt Out</td><td align="center">25</td><td align="center">4.4%</td></tr><tr><td align="left">SP type 2</td><td/><td/></tr><tr><td align="left">&#x02003;Non-neuritic SP</td><td align="center">56</td><td align="center">9.9%</td></tr><tr><td align="left">&#x02003;Neuritic SP</td><td align="center">108</td><td align="center">19.1%</td></tr><tr><td align="left" colspan="2">Semi quantitative SP coverage</td><td/></tr><tr><td align="left">&#x02003;Sparse SP</td><td align="center">90</td><td align="center">16.2%</td></tr><tr><td align="left">&#x02003;Moderate SP</td><td align="center">62</td><td align="center">11.2%</td></tr><tr><td align="left">&#x02003;Frequent SP</td><td align="center">32</td><td align="center">5.8%</td></tr><tr><td align="left"><italic>APOE</italic>&#x003b5;4 carriership</td><td align="center">187</td><td align="center">31.1%</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Senile plaque and neurofibrillary tangle prevalence in the TASTY cohort by age group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Age group (years)</th><th align="center">Total</th><th align="center" colspan="2">Affected (%)</th><th align="center"><italic>P-</italic>value</th><th align="center">Odds Ratio</th><th align="center">95% Confidence Interval</th></tr></thead><tbody><tr><td align="left" colspan="7">Senile plaques</td></tr><tr><td align="left">&#x02003;0 to 49</td><td align="center">119</td><td align="center">7</td><td align="center">5.9</td><td align="center">Ref</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">&#x02003;50 to 59</td><td align="center">101</td><td align="center">17</td><td align="center">16.8</td><td align="center">0.013</td><td align="center">3.24</td><td align="center">1.29 to 8.16</td></tr><tr><td align="left">&#x02003;60 to 69</td><td align="center">89</td><td align="center">21</td><td align="center">23.6</td><td align="center">0.001</td><td align="center">4.94</td><td align="center">1.99 to 12.24</td></tr><tr><td align="left">&#x02003;70 to 79</td><td align="center">130</td><td align="center">56</td><td align="center">43.1</td><td align="center">&#x0003c;0.0001</td><td align="center">12.11</td><td align="center">5.23 to 28.01</td></tr><tr><td align="left">&#x02003;80+</td><td align="center">114</td><td align="center">71</td><td align="center">62.3</td><td align="center">&#x0003c;0.0001</td><td align="center">26.42</td><td align="center">11.27 to 61.96</td></tr><tr><td align="left" colspan="7">Neurofibrillary tangles</td></tr><tr><td align="left">&#x02003;0 to 49</td><td align="center">103</td><td align="center">13</td><td align="center">12.6</td><td align="center">Ref</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">&#x02003;50 to 59</td><td align="center">90</td><td align="center">28</td><td align="center">31.1</td><td align="center">0.002</td><td align="center">3.13</td><td align="center">1.50 to 6.51</td></tr><tr><td align="left">&#x02003;60 to 69</td><td align="center">82</td><td align="center">23</td><td align="center">28.0</td><td align="center">0.010</td><td align="center">2.70</td><td align="center">1.27 to 5.74</td></tr><tr><td align="left">&#x02003;70 to 79</td><td align="center">109</td><td align="center">62</td><td align="center">56.9</td><td align="center">&#x0003c;0.0001</td><td align="center">9.13</td><td align="center">4.56 to 18.28</td></tr><tr><td align="left">&#x02003;80+</td><td align="center">100</td><td align="center">78</td><td align="center">78.0</td><td align="center">&#x0003c;0.0001</td><td align="center">24.55</td><td align="center">11.60 to 51.95</td></tr></tbody></table><table-wrap-foot><p>Those 'Affected' refers to those cases in the TASTY cohort that are affected by senile plaques or neurofibrillary tangles, accordingly.</p></table-wrap-foot></table-wrap></sec><sec><title><italic>APOE</italic>, <italic>CLU</italic>, <italic>CR1</italic> and <italic>PICALM</italic> associations with SP</title><p>As expected, <italic>APOE</italic>&#x003b5;4 carriership was significantly associated with increased risk of having SP (OR 2.52, <italic>P </italic>&#x0003c; 0.0001, CI 1.72 to 3.68); having both non-neuritic (OR 2.42, <italic>P </italic>= 0.003, CI 1.36 to 4.29) and neuritic SP (OR 2.58, <italic>P </italic>&#x0003c; 0.0001, CI 1.66 to 4.02) compared to no SP; and having primitive (OR 2.53, <italic>P </italic>= 0.010, CI 1.25 to 5.10), classic (OR 2.52, <italic>P </italic>&#x0003c; 0.0001, CI 1.54 to 4.13) and burnt out SP (OR 2.77, <italic>P </italic>= 0.014, CI 1.22 to 6.27) compared to no SP, when evaluated against non &#x003b5;4 carriers (see Table <xref ref-type="table" rid="T3">3</xref>). Results showed similar trends when the cohort was split by gender (data not shown).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Association of senile plaque type with <italic>APOE</italic>, <italic>CLU</italic>, <italic>CR1 </italic>and <italic>PICALM </italic>genotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th align="center" colspan="3">SP</th><th align="center" colspan="3">Diffuse</th><th align="center" colspan="3">Primitive</th><th align="center" colspan="3">Classic</th><th align="center" colspan="3">Burnt out</th></tr><tr><th/><th/><th colspan="3"><hr/></th><th colspan="3"><hr/></th><th colspan="3"><hr/></th><th colspan="3"><hr/></th><th colspan="3"><hr/></th></tr><tr><th/><th align="center">Valid N</th><th align="center">SP</th><th align="center">OR (95% CI)</th><th align="center"><italic>P-</italic>value</th><th align="center">Diffuse</th><th align="center">OR (95% CI)</th><th align="center"><italic>P-</italic>value</th><th align="center">Primitive</th><th align="center">OR (95% CI)</th><th align="center"><italic>P-</italic>value</th><th align="center">Classic</th><th align="center">OR (95% CI)</th><th align="center"><italic>P-</italic>value</th><th align="center">Burnt out</th><th align="center">OR (95% CI)</th><th align="center"><italic>P-v</italic>alue</th></tr></thead><tbody><tr><td align="left"><italic>APOE</italic>&#x003b5;4-<sup>1</sup></td><td align="center">388</td><td align="center">88 (22.7)</td><td align="center">-</td><td align="center">-</td><td align="center">12 (3.1)</td><td align="center">-</td><td align="center">-</td><td align="center">19 (4.9)</td><td align="center">-</td><td align="center">-</td><td align="center">44 (11.3)</td><td align="center">-</td><td align="center">-</td><td align="center">13 (3.4)</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left"><italic>APOE</italic>&#x003b5;4+</td><td align="center">174</td><td align="center">74 (42.5)</td><td align="center">3.2 (2.05 to 4.90)</td><td align="center">&#x0003c;0.0001*</td><td align="center">9 (5.2)</td><td align="center">2.4 (0.97 to 5.86)</td><td align="center">0.059</td><td align="center">16 (9.2)</td><td align="center">2.8 (1.37 to 5.74)</td><td align="center">0.005*</td><td align="center">37 (21.3)</td><td align="center">3.2 (1.83 to 5.48)</td><td align="center">&#x0003c;0.0001*</td><td align="center">12 (6.9)</td><td align="center">3.8 (1.56 to 9.01)</td><td align="center">0.003*</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><italic>CLU </italic>TT<sup>2</sup></td><td align="center">336</td><td align="center">89 (26.5)</td><td align="center">-</td><td align="center">-</td><td align="center">13 (3.9)</td><td align="center">-</td><td align="center">-</td><td align="center">22 (6.5)</td><td align="center">-</td><td align="center">-</td><td align="center">48 (14.3)</td><td align="center">-</td><td align="center">-</td><td align="center">6 (1.8)</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left"><italic>CLU </italic>C+</td><td align="center">194</td><td align="center">60 (30.9)</td><td align="center">1.1 (0.73 to 1.76)</td><td align="center">0.570</td><td align="center">6 (3.1)</td><td align="center">0.79 (0.29 to 2.14)</td><td align="center">0.641</td><td align="center">11 (5.7)</td><td align="center">0.9 (0.39 to 1.84)</td><td align="center">0.680</td><td align="center">27 (13.9)</td><td align="center">0.99 (0.56 to 1.77)</td><td align="center">0.988</td><td align="center">16 (8.2)</td><td align="center">4.4 (1.61 to 12.2)</td><td align="center">0.004*</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><italic>CR1 </italic>AA<sup>2</sup></td><td align="center">186</td><td align="center">56 (30.1)</td><td align="center">-</td><td align="center">-</td><td align="center">8 (4.3)</td><td align="center">-</td><td align="center">-</td><td align="center">9 (4.8)</td><td align="center">-</td><td align="center">-</td><td align="center">28 (15.1)</td><td align="center">-</td><td align="center">-</td><td align="center">11 (5.9)</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left"><italic>CR1 </italic>C+</td><td align="center">361</td><td align="center">102 (28.3)</td><td align="center">0.9 (0.62 to 1.54)</td><td align="center">0.924</td><td align="center">12 (3.3)</td><td align="center">0.71 (0.28 to 1.80)</td><td align="center">0.475</td><td align="center">24 (6.6)</td><td align="center">1.2 (0.55 to 2.77)</td><td align="center">0.611</td><td align="center">53 (14.7)</td><td align="center">0.85 (0.48 to 1.49)</td><td align="center">0.572</td><td align="center">13 (3.6)</td><td align="center">0.57 (0.24 to 1.40)</td><td align="center">0.221</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><italic>PICALM </italic>CC<sup>2</sup></td><td align="center">219</td><td align="center">71 (32.4)</td><td align="center">-</td><td align="center">-</td><td align="center">7 (3.2)</td><td align="center">-</td><td align="center">-</td><td align="center">19 (8.7)</td><td align="center">-</td><td align="center">-</td><td align="center">37 (16.9)</td><td align="center">-</td><td align="center">-</td><td align="center">8 (3.7)</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left"><italic>PICALM </italic>T+</td><td align="center">327</td><td align="center">87 (26.6)</td><td align="center">0.6 (0.41 to 0.95)</td><td align="center">0.028*</td><td align="center">12 (3.7)</td><td align="center">1.09 (0.42 to 2.84)</td><td align="center">0.864</td><td align="center">16 (4.9)</td><td align="center">0.5 (0.26 to 1.09)</td><td align="center">0.086</td><td align="center">42 (12.8)</td><td align="center">0.73 (0.42 to 1.25)</td><td align="center">0.253</td><td align="center">17 (5.2)</td><td align="center">1.36 (0.55 to 3.39)</td><td align="center">0.508</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: <italic>APOE </italic>, Apolipoprotein E; CI, confidence intervals; <italic>CLU </italic>, Clusterin; <italic>CR1</italic>, complement component (3b/4b) receptor 1; N, number of cases; OR, odds ratio; <italic>PICALM</italic>, phosphatidylinositol-binding clathrin assembly protein; SP, senile plaques; No SP was the reference group. Numbers in brackets are percentages, unless otherwise stated. In some cases it was impossible to obtain all variables due to technical difficulties and sample damage.</p><p>* Denotes statistically significant values.</p><p><sup>1 </sup>Denotes reference group used for statistical analyses. Age was used as a covariate.</p><p><sup>2 </sup>Denotes most common homozygous genotype and used as the reference group for statistical analyses. <italic>APOE</italic>&#x003b5;4 carriership and age were used as covariates.</p></table-wrap-foot></table-wrap><p><italic>APOE</italic>&#x003b5;4 carriers, compared to &#x003b5;3-&#x003b5;3 carriers, were significantly associated with an increased risk of having SP in all age groups except the youngest and oldest (Figure <xref ref-type="fig" rid="F1">1</xref>). There was a trend of age-related increases in SP, especially of the neuritic type, across all studied genotypes. The <italic>APOE</italic>&#x003b5;2 carrier group was too small to investigate supposed protective effects, although previously published results suggest tendencies towards protection [<xref ref-type="bibr" rid="B16">16</xref>]. In <italic>APOE</italic>&#x003b5;4 adjusted analyses, 80+ year old carriers of the rare TT genotype of <italic>PICALM </italic>had a significantly lower incidence of SP compared to the common CC carriers (OR 0.18, <italic>P </italic>= 0.025, CI 0.04 to 0.81) (see Figure <xref ref-type="fig" rid="F1">1</xref>). This association was not seen among younger age groups. There were no significant associations between genotypes of <italic>CLU </italic>and <italic>CR1 </italic>and SP prevalence.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Senile plaque prevalence by age and genotype (<italic>APOE, CLU, CR1 </italic>and <italic>PICALM</italic>)</bold>. CI = confidence interval; OR = odds ratio.</p></caption><graphic xlink:href="alzrt71-1"/></fig><p>Grouping the rare homozygote and heterozygotes versus the common homozygotes for the SNPs uncovered statistically significant associations between the T allele of <italic>PICALM </italic>and SP (OR 0.62, <italic>P </italic>= 0.028, CI 0.41 to 0.95, versus CC genotype). When we divided the SP into diffuse, primitive, classic and burnt out phenotypes (to investigate the particular phases of the SP life cycle), we found that the rare C allele of <italic>CLU </italic>was significantly associated with the presence of late stage SP (OR 4.4, <italic>P </italic>= 0.004, CI 1.61 to 12.2) compared to the common TT genotype (Table <xref ref-type="table" rid="T3">3</xref>). In that setting, the statistically significant association of the <italic>PICALM </italic>T allele was lost.</p></sec><sec><title><italic>APOE</italic>, <italic>CLU</italic>, <italic>CR1</italic> and <italic>PICALM</italic> associations with SP frequency</title><p>When analyses were performed with SP frequency as the dependent variable, <italic>APOE</italic>&#x003b5;4 carriership was again found to be highly significantly associated with increasing SP coverage, compared to &#x003b5;3-&#x003b5;3 carriers (see Table <xref ref-type="table" rid="T4">4</xref>). <italic>PICALM </italic>TC genotypes (versus CC genotype) were significantly less likely to have moderate SP compared to no SP (OR 0.42, <italic>P </italic>= 0.012, CI 0.21 to 0.83), whilst <italic>CR1 </italic>CC genotype carriers (compared to AA genotype) were more likely to have sparse SP than no SP (OR 2.1, <italic>P </italic>= 0.048, CI 1.01 to 4.43).</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Association of senile plaque coverage with <italic>APOE</italic>, <italic>CLU</italic>, <italic>CR1 </italic>and <italic>PICALM </italic>genotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th/><th align="center" colspan="3">Sparse SP</th><th align="center" colspan="3">Moderate SP</th><th align="center" colspan="3">Frequent SP</th></tr><tr><th/><th/><th/><th colspan="3"><hr/></th><th colspan="3"><hr/></th><th colspan="3"><hr/></th></tr><tr><th/><th align="center">Valid N</th><th align="center">No SP</th><th align="center">Sparse SP</th><th align="center">OR (95% CI)</th><th align="center"><italic>P-</italic>value</th><th align="center">Moderate SP</th><th align="center">OR (95% CI)</th><th align="center"><italic>P-</italic>value</th><th align="center">Frequent SP</th><th align="center">OR (95% CI)</th><th align="center"><italic>P-v</italic>alue</th></tr></thead><tbody><tr><td align="left"><italic>APOE</italic>&#x003b5;4-<sup>1</sup></td><td align="center">378</td><td align="center">281 (74.3)</td><td align="center">51 (13.5)</td><td align="center">-</td><td align="center">-</td><td align="center">29 (7.7)</td><td align="center">-</td><td align="center">-</td><td align="center">17 (4.5)</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left"><italic>APOE</italic>&#x003b5;4+</td><td align="center">174</td><td align="center">89 (51.1)</td><td align="center">39 (22.4)</td><td align="center">2.86 (1.73 to 4.74)</td><td align="center">&#x0003c;0.0001*</td><td align="center">32 (18.4)</td><td align="center">5.32 (2.81 to 10.06)</td><td align="center">&#x0003c;0.0001*</td><td align="center">14 (8.0)</td><td align="center">3.97 (1.76 to 8.94)</td><td align="center">0.001*</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><italic>CLU </italic>TT<sup>2</sup></td><td align="center">329</td><td align="center">227 (69.0)</td><td align="center">48 (14.6)</td><td align="center">-</td><td align="center">-</td><td align="center">33 (10.0)</td><td align="center">-</td><td align="center">-</td><td align="center">21 (6.4)</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left"><italic>CLU </italic>C+</td><td align="center">192</td><td align="center">123 (64.1)</td><td align="center">37 (19.3)</td><td align="center">1.26 (0.76 to 2.09)</td><td align="center">0.378</td><td align="center">23 (12.0)</td><td align="center">1.06 (0.55 to 2.03)</td><td align="center">0.873</td><td align="center">9 (4.7)</td><td align="center">0.68 (0.29 to 1.63)</td><td align="center">0.391</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><italic>CR1 </italic>AA<sup>2</sup></td><td align="center">182</td><td align="center">125 (68.7)</td><td align="center">22 (12.1)</td><td align="center">-</td><td align="center">-</td><td align="center">21 (11.5)</td><td align="center">-</td><td align="center">-</td><td align="center">14 (7.7)</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left"><italic>CR1 </italic>C+</td><td align="center">355</td><td align="center">234 (65.9)</td><td align="center">65 (18.3)</td><td align="center">1.48 (0.85 to 2.58)</td><td align="center">0.167</td><td align="center">38 (10.7)</td><td align="center">0.92 (0.48 to 1.78)</td><td align="center">0.807</td><td align="center">18 (5.1)</td><td align="center">0.62 (0.28 to 1.38)</td><td align="center">0.242</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align="left"><italic>PICALM </italic>CC<sup>2</sup></td><td align="center">217</td><td align="center">136 (62.7)</td><td align="center">33 (15.2)</td><td align="center">-</td><td align="center">-</td><td align="center">32 (14.7)</td><td align="center">-</td><td align="center">-</td><td align="center">16 (7.4)</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left"><italic>PICALM </italic>T+</td><td align="center">319</td><td align="center">222 (69.6)</td><td align="center">54 (16.9)</td><td align="center">0.97 (0.58 to 1.60)</td><td align="center">0.898</td><td align="center">27 (8.5)</td><td align="center">0.43 (0.23 to 0.82)</td><td align="center">0.010*</td><td align="center">16 (5.0)</td><td align="center">0.58 (0.26 to 1.26)</td><td align="center">0.169</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: <italic>APOE </italic>, Apolipoprotein E; CI, confidence intervals; <italic>CLU </italic>, Clusterin; <italic>CR1</italic>, complement component (3b/4b) receptor 1; N, number of cases; OR, odds ratio; <italic>PICALM</italic>, phosphatidylinositol-binding clathrin assembly protein; SP, senile plaques. No SP was the reference group. Numbers in brackets are percentages, unless otherwise stated. In some cases it was impossible to obtain all variables due to technical difficulties and sample damage.</p><p>* Denotes statistically significant values.</p><p><sup>1 </sup>Denotes reference group used for statistical analyses. Age was used as a covariate.</p><p><sup>2 </sup>Denotes most common homozygous genotype and used as the reference group for statistical analyses. <italic>APOE</italic>&#x003b5;4 carriership and age were used as covariates.</p></table-wrap-foot></table-wrap><p>When we grouped the rare homozygote and heterozygotes together versus the common homozygotes (Table <xref ref-type="table" rid="T4">4</xref>), significance was lost for <italic>CR1</italic>, however <italic>PICALM </italic>T allele carriers remained less likely to have coverage of SP versus no SP compared to CC genotype, however again statistical significance was only reached for moderate SP (OR 0.43, <italic>P </italic>= 0.010, CI 0.23 to 0.82).</p></sec><sec><title>Associations with gender</title><p>Reanalysing the significant associations with the cohort split by gender gave similar results (data not shown), with females generally more strongly associated, most likely due to their older age. No further significant associations were uncovered.</p></sec><sec><title>Associations with A&#x003b2; staining</title><p>A subpopulation of the cohort were assessed for associations with immunohistochemical staining (<italic>n </italic>= 152). None of the newly identified SNPs were statistically significantly associated with A&#x003b2; staining, as seen in Figure <xref ref-type="fig" rid="F2">2</xref>. <italic>APOE</italic>&#x003b5;4 carriership, however, was significantly associated with higher cortical coverage of A&#x003b2; staining (<italic>P </italic>&#x0003c; 0.0001).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Boxplots of cortical SP coverage (%) according to A&#x003b2; staining and genotype (<italic>APOE, CLU, CR1 </italic>and <italic>PICALM</italic>)</bold>.</p></caption><graphic xlink:href="alzrt71-2"/></fig></sec></sec><sec><title>Discussion</title><p>AD is the most common form of dementia, but to date its aetiology has remained elusive, despite intensive research. The proposed causes of AD relate to neuropathological findings post-mortem, which is the only way to definitively confirm a patient's diagnosis [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Diagnosis of the first AD patient, back in 1906, revealed large numbers of SP and NFT; however, although new treatments aimed at reversing the disease by reducing SP have proven successful, they have been without improvements in cognitive abilities of patients [<xref ref-type="bibr" rid="B35">35</xref>]. Furthermore, studies have shown cognitively normal elderly can also have large numbers of these brain lesions [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B19">19</xref>] and not all AD cases have the required amounts to corroborate cognitive dysfunction [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>Genome wide association studies (GWAS) investigating AD have in the past not been powerful enough to reveal anything except <italic>APOE</italic>. Two recent large GWAS [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>], however, collectively investigated over 30,000 individuals (with almost 12,000 probable AD cases) and examined around 500,000 SNPs that may influence AD risk.</p><p>We recently showed that SP and NFT were surprisingly common in a non-demented autopsy series, which represents the closest model to a population sample and that the occurrence of SP, but not NFT, was strongly affected by the <italic>APOE</italic>&#x003b5;4 allele, regardless of age [<xref ref-type="bibr" rid="B16">16</xref>]. Because of the GWAS' discoveries of three potential new candidates for AD risk, we decided to look at their associations with the neuropathological lesions SP and NFT in our cohort to investigate their involvement in the development of these brain lesions.</p><p>SP associated with both age and gender, and the <italic>APOE</italic>&#x003b5;4 allele was highly associated with SP in many of our analyses. Additional analyses showed that the <italic>APOE</italic>&#x003b5;4 associations were extremely robust in the TASTY series, thus validating our cohort's ability to detect associations with the measured brain lesions. However, whilst NFT were found to associate with age and gender, they were not associated with any of the SNPs investigated. The strong association seen between males and SP prevalence, and females and NFT occurrence may be a confounding factor, due to the older average age of females in the cohort. Additionally, our cohort may over-represent early and violent deaths; however, all cases were included to best represent a population-based investigation.</p><p>We hypothesised that the three other SNPs (<italic>CLU</italic>, <italic>CR1 </italic>and <italic>PICALM</italic>) would also associate with SP, as they are involved in AD pathways and most likely would be associated with the development of brain lesions [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B34">34</xref>]. Our results indicate that we did not find as many robust correlations as for <italic>APOE</italic>.</p><p>Genetic variants of <italic>CLU</italic>, <italic>PICALM </italic>and <italic>CR1 </italic>genes were associated with SP and remained so with the inclusion of <italic>APOE</italic>&#x003b5;4 carriers and age as covariates. The appearance of an increased risk for <italic>CLU </italic>C carriers versus TT is unusual in that it only applies for Burnt Out SP - a group in the cohort that is relatively small and are majority females. This suggests that the effect of <italic>CLU </italic>could be on the later stages of SP development and related to removal of A&#x003b2; [<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B34">34</xref>] being reduced in efficiency.</p><p>The <italic>PICALM </italic>T allele appears to have a protective effect on SP prevalence, true also for TT genotypes, versus CC genotypes in the oldest age group. This may be due to more efficient intracellular trafficking and clear-up of A&#x003b2;, or the components or pathways that induce A&#x003b2; build-up or production [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B27">27</xref>]. The protective effect of the T carriers was seen also for SP coverage; however, it was only significant for moderate SP.</p><p><italic>CR1 </italic>CC genotype carriers were associated with an increased risk of having sparse compared to no SP; however, the trend was not consistent for increasing coverage of SP (data not shown), which was also true for the analysis grouping the rare homozygote with the heterozygotes. This suggests the effect of <italic>CR1 </italic>is complex and not as straight-forward as increasing SP risk and requires further investigation.</p><p>The lack of robust and numerous associations with the GWAS SNPs and brain lesions, alongside the strong <italic>APOE</italic>&#x003b5;4 results, questions the involvement of SP in AD pathology. It may be a coincidence that SP are found in AD brains with evidence suggesting that they may be a part of normal aging [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. In light of this, SP treatments have so far failed to improve patients' cognitive abilities [<xref ref-type="bibr" rid="B35">35</xref>] and current theories are moving away from SP and suggest soluble oligomeric A&#x003b2; may be the culprit in AD [<xref ref-type="bibr" rid="B36">36</xref>-<xref ref-type="bibr" rid="B39">39</xref>]. The scarcity of associations may be due to the small number of cases with SP within the TASTY series (31.1%), resulting in low power; however, we have a 600 case-strong cohort, which revealed strong associations between <italic>APOE </italic>with SP. It may also be due to the low strength of these prior associations in the original studies, which should be investigated in future cohorts of a similar nature.</p><p>Some may question the use of an autopsy series to investigate an age-dependent illness such as AD; however, the TASTY cohort provides a unique view into the early midlife prevalence of well-defined neuropathological lesions, showing their common prevalence.</p></sec><sec><title>Conclusions</title><p>We have an interesting window into the development of neuropathological lesions and their associations with AD-risk genes in the general population, and as far as we know, this is the first study of its kind. SP were found to associate with age, gender, and <italic>APOE</italic>&#x003b5;4, but not consistently with <italic>CLU</italic>, <italic>CR1 </italic>or <italic>PICALM</italic>, suggesting that these SNPs most likely do not affect the development of the studied neuropathological lesions. Further studies should replicate these findings in a larger autopsy series of the same kind, both with and without AD cases, to define the occurrence of these neuropathological lesions within the context of normal aging.</p><p>Our results suggest that whilst these SNPs are associated with probable AD cases (in the GWAS), they do not strongly relate to SP prevalence, or at all to NFT, in an autopsy series most representative of the general population, possibly indicating their complex involvement in the disease.</p></sec><sec><title>Abbreviations</title><p>AD: Alzheimer's disease; APOE: apolipoprotein E; CI: confidence interval; CLU: clusterin; CR1: complement component (3b/4b) receptor 1; GWAS: genome wide association studies; NFT: neurofibrillary tangles; OR: odds ratio; PICALM: phosphatidylinositol binding clathrin assembly protein; SNPs: single nucleotide polymorphisms; SP: senile plaques; TASTY: Tampere autopsy study.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>All authors contributed to this manuscript. EHK performed experiments and analyses and wrote the manuscript. HH, TL and SH measured the neuropathological lesions. SG and PJK collected the autopsy series. SG, HH and PJK provided comments and discussions on the progress of the manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>Many thanks to Heini Huhtala (for assistance with statistical analyses) and Sari Tuomisto (for assistance with genotyping). This work was supported by funds from the Medical Research Fund of Tampere University Hospital, the Pirkanmaa Regional Fund of the Finnish Cultural Foundation, the Finnish Foundation for Cardiovascular Research, and the Yrj&#x000f6; Jahnsson Foundation.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Polvikoski</surname><given-names>T</given-names></name><name><surname>Sulkava</surname><given-names>R</given-names></name><name><surname>Rastas</surname><given-names>S</given-names></name><name><surname>Sutela</surname><given-names>A</given-names></name><name><surname>Niinist&#x000f6;</surname><given-names>L</given-names></name><name><surname>Notkola</surname><given-names>I</given-names></name><name><surname>Verkkoniemi</surname><given-names>A</given-names></name><name><surname>Viramo</surname><given-names>P</given-names></name><name><surname>Juva</surname><given-names>K</given-names></name><name><surname>Haltia</surname><given-names>M</given-names></name><article-title>Incidence of dementia in very elderly individuals: a clinical, neuropathological and molecular genetic study</article-title><source>Neuroepidemiology</source><year>2006</year><volume>26</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1159/000090252</pub-id><pub-id pub-id-type="pmid">16352910</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Harvey</surname><given-names>DJ</given-names></name><name><surname>Beckett</surname><given-names>LA</given-names></name><name><surname>Mungas</surname><given-names>DM</given-names></name><article-title>Multivariate modeling of two associated cognitive outcomes in a longitudinal study</article-title><source>J Alzheimers Dis</source><year>2003</year><volume>5</volume><fpage>357</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">14646026</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Corder</surname><given-names>E</given-names></name><name><surname>Saunders</surname><given-names>A</given-names></name><name><surname>Strittmatter</surname><given-names>W</given-names></name><name><surname>Schmechel</surname><given-names>D</given-names></name><name><surname>Gaskell</surname><given-names>P</given-names></name><name><surname>Small</surname><given-names>G</given-names></name><name><surname>Roses</surname><given-names>A</given-names></name><name><surname>Haines</surname><given-names>J</given-names></name><name><surname>Pericak-Vance</surname><given-names>M</given-names></name><article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families</article-title><source>Science</source><year>1993</year><volume>261</volume><fpage>921</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1126/science.8346443</pub-id><pub-id pub-id-type="pmid">8346443</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>van Duijn</surname><given-names>C</given-names></name><name><surname>Wehnert</surname><given-names>A</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Havekes</surname><given-names>LM</given-names></name><name><surname>de Knijff</surname><given-names>P</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><article-title>Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease</article-title><source>Nat Genet</source><year>1994</year><volume>7</volume><fpage>74</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1038/ng0594-74</pub-id><pub-id pub-id-type="pmid">8075646</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Farrer</surname><given-names>L</given-names></name><name><surname>Cupples</surname><given-names>L</given-names></name><name><surname>Haines</surname><given-names>J</given-names></name><name><surname>Hyman</surname><given-names>B</given-names></name><name><surname>Kukull</surname><given-names>W</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><name><surname>Pericak-Vance</surname><given-names>M</given-names></name><name><surname>Risch</surname><given-names>N</given-names></name><name><surname>van Duijn</surname><given-names>C</given-names></name><article-title>Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis</article-title><source>JAMA</source><year>1997</year><volume>278</volume><fpage>1349</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1001/jama.278.16.1349</pub-id><pub-id pub-id-type="pmid">9343467</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Coon</surname><given-names>KD</given-names></name><name><surname>Myers</surname><given-names>AJ</given-names></name><name><surname>Craig</surname><given-names>DW</given-names></name><name><surname>Webster</surname><given-names>JA</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>Lince</surname><given-names>DH</given-names></name><name><surname>Zismann</surname><given-names>VL</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Leung</surname><given-names>D</given-names></name><name><surname>Bryden</surname><given-names>L</given-names></name><name><surname>Halperin</surname><given-names>RF</given-names></name><name><surname>Marlowe</surname><given-names>L</given-names></name><name><surname>Kaleem</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>Ravid</surname><given-names>R</given-names></name><name><surname>Heward</surname><given-names>CB</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Papassotiropoulos</surname><given-names>A</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Stephan</surname><given-names>DA</given-names></name><article-title>A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease</article-title><source>J Clin Psychiatry</source><year>2007</year><volume>68</volume><fpage>613</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.4088/JCP.v68n0419</pub-id><pub-id pub-id-type="pmid">17474819</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Mahley</surname><given-names>RW</given-names></name><name><surname>Rall</surname><given-names>SC</given-names><suffix>Jr</suffix></name><article-title>Apolipoprotein E: far more than a lipid transport protein</article-title><source>Annu Rev Genomics Hum Genet</source><year>2000</year><volume>1</volume><fpage>507</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1146/annurev.genom.1.1.507</pub-id><pub-id pub-id-type="pmid">11701639</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Jellinger</surname><given-names>KA</given-names></name><name><surname>Attems</surname><given-names>J</given-names></name><article-title>Prevalence of dementia disorders in the oldest-old: an autopsy study</article-title><source>Acta Neuropathol</source><year>2010</year><volume>119</volume><fpage>421</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0654-5</pub-id><pub-id pub-id-type="pmid">20204386</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Galasko</surname><given-names>D</given-names></name><article-title>Biomarkers in non-Alzheimer dementias</article-title><source>Clin Neurosci Res</source><year>2004</year><volume>3</volume><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.cnr.2004.04.004</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Cavalieri</surname><given-names>M</given-names></name><name><surname>Enzinger</surname><given-names>C</given-names></name><name><surname>Petrovic</surname><given-names>K</given-names></name><name><surname>Pluta-Fuerst</surname><given-names>A</given-names></name><name><surname>Homayoon</surname><given-names>N</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Fazekas</surname><given-names>F</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><article-title>Vascular dementia and Alzheimer's disease - are we in a dead-end road?</article-title><source>Neurodegener Dis</source><year>2010</year><volume>7</volume><fpage>122</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1159/000285521</pub-id><pub-id pub-id-type="pmid">20173341</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Pikkarainen</surname><given-names>M</given-names></name><name><surname>Al-Sarraj</surname><given-names>S</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>Bell</surname><given-names>J</given-names></name><name><surname>Bodi</surname><given-names>I</given-names></name><name><surname>Bogdanovic</surname><given-names>N</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name><name><surname>Bugiani</surname><given-names>O</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Graeber</surname><given-names>MB</given-names></name><name><surname>Hauw</surname><given-names>J</given-names></name><name><surname>Kamphorst</surname><given-names>W</given-names></name><name><surname>King</surname><given-names>A</given-names></name><name><surname>Kopp</surname><given-names>N</given-names></name><name><surname>Korkolopoulou</surname><given-names>P</given-names></name><name><surname>Kov&#x000e1;cs</surname><given-names>GG</given-names></name><name><surname>Meyronet</surname><given-names>D</given-names></name><name><surname>Parchi</surname><given-names>P</given-names></name><name><surname>Patsouris</surname><given-names>E</given-names></name><name><surname>Preusser</surname><given-names>M</given-names></name><name><surname>Ravid</surname><given-names>R</given-names></name><name><surname>Roggendorf</surname><given-names>W</given-names></name><name><surname>Seilhean</surname><given-names>D</given-names></name><name><surname>Streichenberger</surname><given-names>N</given-names></name><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Kretzschmar</surname><given-names>H</given-names></name><article-title>Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium</article-title><source>J Neuropathol Exp Neurol</source><year>2006</year><volume>65</volume><fpage>740</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1097/01.jnen.0000229986.17548.27</pub-id><pub-id pub-id-type="pmid">16896308</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Duyckaerts</surname><given-names>C</given-names></name><name><surname>Delatour</surname><given-names>B</given-names></name><name><surname>Potier</surname><given-names>M</given-names></name><article-title>Classification and basic pathology of Alzheimer disease</article-title><source>Acta Neuropathol</source><year>2009</year><volume>118</volume><fpage>5</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s00401-009-0532-1</pub-id><pub-id pub-id-type="pmid">19381658</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol</source><year>1991</year><volume>82</volume><fpage>239</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1007/BF00308809</pub-id><pub-id pub-id-type="pmid">1759558</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Mirra</surname><given-names>SS</given-names></name><name><surname>Heyman</surname><given-names>A</given-names></name><name><surname>McKeel</surname><given-names>D</given-names></name><name><surname>Sumi</surname><given-names>SM</given-names></name><name><surname>Crain</surname><given-names>BJ</given-names></name><name><surname>Brownlee</surname><given-names>LM</given-names></name><name><surname>Vogel</surname><given-names>FS</given-names></name><name><surname>Hughes</surname><given-names>JP</given-names></name><name><surname>van Belle</surname><given-names>G</given-names></name><name><surname>Berg</surname><given-names>L</given-names></name><article-title>The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease</article-title><source>Neurology</source><year>1991</year><volume>41</volume><fpage>479</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">2011243</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Flory</surname><given-names>M</given-names></name><name><surname>Khatoon</surname><given-names>S</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Pirttila</surname><given-names>T</given-names></name><name><surname>Lehtovirta</surname><given-names>M</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><article-title>Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers</article-title><source>Ann Neurol</source><year>2005</year><volume>58</volume><fpage>748</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1002/ana.20639</pub-id><pub-id pub-id-type="pmid">16247771</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Kok</surname><given-names>E</given-names></name><name><surname>Haikonen</surname><given-names>S</given-names></name><name><surname>Luoto</surname><given-names>T</given-names></name><name><surname>Huhtala</surname><given-names>H</given-names></name><name><surname>Goebeler</surname><given-names>S</given-names></name><name><surname>Haapasalo</surname><given-names>H</given-names></name><name><surname>Karhunen</surname><given-names>P</given-names></name><article-title>Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age</article-title><source>Ann Neurol</source><year>2009</year><volume>65</volume><fpage>650</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1002/ana.21696</pub-id><pub-id pub-id-type="pmid">19557866</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Ghebremedhin</surname><given-names>E</given-names></name><name><surname>Schultz</surname><given-names>C</given-names></name><name><surname>Thal</surname><given-names>D</given-names></name><name><surname>Rub</surname><given-names>U</given-names></name><name><surname>Ohm</surname><given-names>T</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name><article-title>Gender and age modify the association between APOE and AD-related neuropathology</article-title><source>Neurology</source><year>2001</year><volume>56</volume><fpage>1696</fpage><lpage>1701</lpage><pub-id pub-id-type="pmid">11425936</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Savva</surname><given-names>GM</given-names></name><name><surname>Wharton</surname><given-names>SB</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>Forster</surname><given-names>G</given-names></name><name><surname>Matthews</surname><given-names>FE</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><article-title>Age, neuropathology, and dementia</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>2302</fpage><lpage>2309</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0806142</pub-id><pub-id pub-id-type="pmid">19474427</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Nicoll</surname><given-names>J</given-names></name><name><surname>Savva</surname><given-names>GM</given-names></name><name><surname>Stewart</surname><given-names>J</given-names></name><name><surname>Matthews</surname><given-names>FE</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Ince</surname><given-names>P</given-names></name><article-title>Association between APOE genotype, neuropathology and dementia in the older population of England and Wales</article-title><source>Neuropathol Appl Neurobiol</source><year>2011</year><volume>37</volume><fpage>285</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2010.01130.x</pub-id><pub-id pub-id-type="pmid">20880354</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Tanzi</surname><given-names>R</given-names></name><name><surname>Kovacs</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Moir</surname><given-names>K</given-names></name><name><surname>Guenette</surname><given-names>S</given-names></name><name><surname>Wasco</surname><given-names>W</given-names></name><article-title>The gene defects responsible for familial Alzheimer's disease</article-title><source>Neurobiol Dis</source><year>1996</year><volume>3</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1006/nbdi.1996.0016</pub-id><pub-id pub-id-type="pmid">8980016</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Rapoport</surname><given-names>M</given-names></name><name><surname>Dawson</surname><given-names>HN</given-names></name><name><surname>Binder</surname><given-names>LI</given-names></name><name><surname>Vitek</surname><given-names>MP</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name><article-title>Tau is essential to beta-amyloid-induced neurotoxicity</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>6364</fpage><lpage>6369</lpage><pub-id pub-id-type="doi">10.1073/pnas.092136199</pub-id><pub-id pub-id-type="pmid">11959919</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Lambert</surname><given-names>JC</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><name><surname>Even</surname><given-names>G</given-names></name><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Sleegers</surname><given-names>K</given-names></name><name><surname>Hiltunen</surname><given-names>M</given-names></name><name><surname>Combarros</surname><given-names>O</given-names></name><name><surname>Zelenika</surname><given-names>D</given-names></name><name><surname>Bullido</surname><given-names>MJ</given-names></name><name><surname>Tavernier</surname><given-names>B</given-names></name><name><surname>Letenneur</surname><given-names>L</given-names></name><name><surname>Bettens</surname><given-names>K</given-names></name><name><surname>Berr</surname><given-names>C</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Fi&#x000e9;vet</surname><given-names>N</given-names></name><name><surname>Barberger-Gateau</surname><given-names>P</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>De Deyn</surname><given-names>P</given-names></name><name><surname>Mateo</surname><given-names>I</given-names></name><name><surname>Franck</surname><given-names>A</given-names></name><name><surname>Helisalmi</surname><given-names>S</given-names></name><name><surname>Porcellini</surname><given-names>E</given-names></name><name><surname>Hanon</surname><given-names>O</given-names></name><collab>the European Alzheimer's Disease Initiative Investigators</collab><name><surname>de Pancorbo</surname><given-names>MM</given-names></name><name><surname>Lendon</surname><given-names>C</given-names></name><name><surname>Dufouil</surname><given-names>C</given-names></name><name><surname>Jaillard</surname><given-names>C</given-names></name><name><surname>Leveillard</surname><given-names>T</given-names></name><name><surname>Alvarez</surname><given-names>V</given-names></name><etal/><article-title>Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>1094</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1038/ng.439</pub-id><pub-id pub-id-type="pmid">19734903</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Harold</surname><given-names>D</given-names></name><name><surname>Abraham</surname><given-names>R</given-names></name><name><surname>Hollingworth</surname><given-names>P</given-names></name><name><surname>Sims</surname><given-names>R</given-names></name><name><surname>Gerrish</surname><given-names>A</given-names></name><name><surname>Hamshere</surname><given-names>ML</given-names></name><name><surname>Pahwa</surname><given-names>JS</given-names></name><name><surname>Moskvina</surname><given-names>V</given-names></name><name><surname>Dowzell</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>N</given-names></name><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Stretton</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>AR</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name><name><surname>Powell</surname><given-names>J</given-names></name><name><surname>Proitsi</surname><given-names>P</given-names></name><name><surname>Lupton</surname><given-names>MK</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Lawlor</surname><given-names>B</given-names></name><name><surname>Lynch</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>KS</given-names></name><name><surname>Passmore</surname><given-names>PA</given-names></name><name><surname>Craig</surname><given-names>D</given-names></name><name><surname>McGuinness</surname><given-names>B</given-names></name><name><surname>Todd</surname><given-names>S</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><etal/><article-title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>1088</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1038/ng.440</pub-id><pub-id pub-id-type="pmid">19734902</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Tebar</surname><given-names>F</given-names></name><name><surname>Bohlander</surname><given-names>S</given-names></name><name><surname>Sorkin</surname><given-names>A</given-names></name><article-title>Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic</article-title><source>Mol Biol Cell</source><year>1999</year><volume>10</volume><fpage>2687</fpage><lpage>2702</lpage><pub-id pub-id-type="pmid">10436022</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Yao</surname><given-names>P</given-names></name><name><surname>Petralia</surname><given-names>R</given-names></name><name><surname>Bushlin</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Furukawa</surname><given-names>K</given-names></name><article-title>Synaptic distribution of the endocytic accessory proteins AP180 and CALM</article-title><source>J Comp Neurol</source><year>2005</year><volume>481</volume><fpage>58</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1002/cne.20362</pub-id><pub-id pub-id-type="pmid">15558718</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Dreyling</surname><given-names>M</given-names></name><name><surname>Martinez-Climent</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Rowley</surname><given-names>J</given-names></name><name><surname>Bohlander</surname><given-names>S</given-names></name><article-title>The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>4804</fpage><lpage>4809</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.10.4804</pub-id><pub-id pub-id-type="pmid">8643484</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Kuo</surname><given-names>Y</given-names></name><name><surname>Kokjohn</surname><given-names>T</given-names></name><name><surname>Kalback</surname><given-names>W</given-names></name><name><surname>Luehrs</surname><given-names>D</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Chevallier</surname><given-names>N</given-names></name><name><surname>Koo</surname><given-names>E</given-names></name><name><surname>Emmerling</surname><given-names>M</given-names></name><name><surname>Roher</surname><given-names>A</given-names></name><article-title>Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma</article-title><source>Biochem Biophys Res Commun</source><year>2000</year><volume>268</volume><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.2222</pub-id><pub-id pub-id-type="pmid">10679277</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Mastroeni</surname><given-names>D</given-names></name><name><surname>Grover</surname><given-names>A</given-names></name><name><surname>Leonard</surname><given-names>B</given-names></name><name><surname>Ahern</surname><given-names>G</given-names></name><name><surname>Cao</surname><given-names>P</given-names></name><name><surname>Kolody</surname><given-names>H</given-names></name><name><surname>Vedders</surname><given-names>L</given-names></name><name><surname>Kolb</surname><given-names>W</given-names></name><name><surname>Sabbagh</surname><given-names>M</given-names></name><article-title>Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes</article-title><source>Neurobiol Aging</source><year>2006</year><volume>27</volume><fpage>1733</fpage><lpage>1739</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.09.043</pub-id><pub-id pub-id-type="pmid">16290270</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Fonseca</surname><given-names>M</given-names></name><name><surname>Pisalyaput</surname><given-names>K</given-names></name><name><surname>Tenner</surname><given-names>A</given-names></name><article-title>Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease</article-title><source>J Neurochem</source><year>2008</year><volume>106</volume><fpage>2080</fpage><lpage>2092</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05558.x</pub-id><pub-id pub-id-type="pmid">18624920</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>AH</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name><name><surname>Alexander</surname><given-names>JJ</given-names></name><name><surname>Quigg</surname><given-names>R</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><article-title>Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>10837</fpage><lpage>10842</lpage><pub-id pub-id-type="doi">10.1073/pnas.162350199</pub-id><pub-id pub-id-type="pmid">12119423</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Jenne</surname><given-names>D</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name><article-title>Clusterin: the intriguing guises of a widely expressed glycoprotein</article-title><source>Trends Biochem Sci</source><year>1992</year><volume>17</volume><fpage>154</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/0968-0004(92)90325-4</pub-id><pub-id pub-id-type="pmid">1585460</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Jomary</surname><given-names>C</given-names></name><article-title>Clusterin</article-title><source>Int J Biochem Cell Biol</source><year>2002</year><volume>34</volume><fpage>427</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/S1357-2725(01)00155-8</pub-id><pub-id pub-id-type="pmid">11906815</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>DeMattos</surname><given-names>RB</given-names></name><name><surname>Cirrito</surname><given-names>JR</given-names></name><name><surname>Parsadanian</surname><given-names>M</given-names></name><name><surname>May</surname><given-names>PC</given-names></name><name><surname>O'Dell</surname><given-names>MA</given-names></name><name><surname>Taylor</surname><given-names>JW</given-names></name><name><surname>Harmony</surname><given-names>JA</given-names></name><name><surname>Aronow</surname><given-names>BJ</given-names></name><name><surname>Bales</surname><given-names>KR</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><article-title>ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism <italic>in vivo</italic></article-title><source>Neuron</source><year>2004</year><volume>41</volume><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(03)00850-X</pub-id><pub-id pub-id-type="pmid">14741101</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Calero</surname><given-names>M</given-names></name><name><surname>Rostagno</surname><given-names>A</given-names></name><name><surname>Matsubara</surname><given-names>E</given-names></name><name><surname>Zlokovic</surname><given-names>B</given-names></name><name><surname>Frangione</surname><given-names>B</given-names></name><name><surname>Ghiso</surname><given-names>J</given-names></name><article-title>Apolipoprotein J (clusterin) and Alzheimer's disease</article-title><source>Microsc Res Tech</source><year>2000</year><volume>50</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1002/1097-0029(20000815)50:4&#x0003c;305::AID-JEMT10&#x0003e;3.0.CO;2-L</pub-id><pub-id pub-id-type="pmid">10936885</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Boche</surname><given-names>D</given-names></name><name><surname>Wilkinson</surname><given-names>D</given-names></name><name><surname>Yadegarfar</surname><given-names>G</given-names></name><name><surname>Hopkins</surname><given-names>V</given-names></name><name><surname>Bayer</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>RW</given-names></name><name><surname>Bullock</surname><given-names>R</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Neal</surname><given-names>JW</given-names></name><name><surname>Zotova</surname><given-names>E</given-names></name><name><surname>Nicoll</surname><given-names>JA</given-names></name><article-title>Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>216</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61075-2</pub-id><pub-id pub-id-type="pmid">18640458</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Gandy</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>AJ</given-names></name><name><surname>Steele</surname><given-names>JW</given-names></name><name><surname>Lublin</surname><given-names>AL</given-names></name><name><surname>Lah</surname><given-names>JJ</given-names></name><name><surname>Walker</surname><given-names>LC</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Krafft</surname><given-names>GA</given-names></name><name><surname>Levy</surname><given-names>E</given-names></name><name><surname>Checler</surname><given-names>F</given-names></name><name><surname>Glabe</surname><given-names>C</given-names></name><name><surname>Bilker</surname><given-names>WB</given-names></name><name><surname>Abel</surname><given-names>T</given-names></name><name><surname>Schmeidler</surname><given-names>J</given-names></name><name><surname>Ehrlich</surname><given-names>ME</given-names></name><article-title>Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers</article-title><source>Ann Neurol</source><year>2010</year><volume>68</volume><fpage>220</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">20641005</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Moir</surname><given-names>RD</given-names></name><name><surname>Tseitlin</surname><given-names>KA</given-names></name><name><surname>Soscia</surname><given-names>S</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Irizarry</surname><given-names>MC</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name><article-title>Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>17458</fpage><lpage>17463</lpage><pub-id pub-id-type="doi">10.1074/jbc.M414176200</pub-id><pub-id pub-id-type="pmid">15728175</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Tomiyama</surname><given-names>T</given-names></name><name><surname>Matsuyama</surname><given-names>S</given-names></name><name><surname>Iso</surname><given-names>H</given-names></name><name><surname>Umeda</surname><given-names>T</given-names></name><name><surname>Takuma</surname><given-names>H</given-names></name><name><surname>Ohnishi</surname><given-names>K</given-names></name><name><surname>Ishibashi</surname><given-names>K</given-names></name><name><surname>Teraoka</surname><given-names>R</given-names></name><name><surname>Sakama</surname><given-names>N</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Nishitsuji</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Lambert</surname><given-names>MP</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><article-title>A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss <italic>in vivo</italic></article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>4845</fpage><lpage>4856</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5825-09.2010</pub-id><pub-id pub-id-type="pmid">20371804</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1126/science.1072994</pub-id><pub-id pub-id-type="pmid">12130773</pub-id></mixed-citation></ref></ref-list></back></article>